0001209191-22-024136.txt : 20220412
0001209191-22-024136.hdr.sgml : 20220412
20220412161017
ACCESSION NUMBER: 0001209191-22-024136
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220408
FILED AS OF DATE: 20220412
DATE AS OF CHANGE: 20220412
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Flannelly Barry P
CENTRAL INDEX KEY: 0001615842
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12400
FILM NUMBER: 22822383
MAIL ADDRESS:
STREET 1: ROUTE 141 AND HENRY CLAY ROAD
CITY: WILMINGTON
STATE: DE
ZIP: 19880
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INCYTE CORP
CENTRAL INDEX KEY: 0000879169
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 943136539
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
BUSINESS PHONE: 3024986700
MAIL ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE CORP
DATE OF NAME CHANGE: 20030318
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE GENOMICS INC
DATE OF NAME CHANGE: 20000710
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930902
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-04-08
0
0000879169
INCYTE CORP
INCY
0001615842
Flannelly Barry P
1801 AUGUSTINE CUT-OFF
WILMINGTON
DE
19803
0
1
0
0
EVP & General Manager US
Common Stock
2022-04-08
4
M
0
20516
68.62
A
87808
D
Common Stock
2022-04-08
4
S
0
20516
83.01
D
67292
D
Common Stock
2022-04-08
4
M
0
21348
72.27
A
88640
D
Common Stock
2022-04-08
4
S
0
21348
84.00
D
67292
D
Common Stock
2022-04-08
4
S
0
881
82.96
D
66411
D
Common Stock
2022-04-08
4
S
0
1248
82.96
D
65163
D
Non-Qualified Stock Option (right to buy)
68.62
2022-04-08
4
M
0
20516
0.00
D
2028-07-01
Common Stock
20516
0
D
Non-Qualified Stock Option (right to buy)
72.27
2022-04-08
4
M
0
21348
0.00
D
2029-01-03
Common Stock
21348
0
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.
Includes an aggregate of 64,148 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.
Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2019 and the remainder vesting monthly over three years.
Beginning January 4, 2019, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2019 and the remainder vesting monthly over three years.
/s/ Barry Flannelly
2022-04-12